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Abstract. The protection against colorectal cancer (CRC)
by non-steroidal anti-inflammatory drugs (NSAIDs) is in part
dependent on inhibition of cyclooxygenase (COX). We
compared the efficacy of the non-COX-inhibiting R
flurbiprofen (R-FB) with COX-inhibiting sulindac and
racemic flurbiprofen (Rac-FB), and determined their effects
on apoptosis, in an azoxymethane (AOM)-induced rat CRC
model. In experiment 1, groups of rats were given daily drug
gavage (R-FB 30 mg/kg, Rac-FB 10 mg/kg and Sulindac 20
mg/kg) for one week, followed by AOM treatment and were
killed eight hours later, colons were examined for apoptosis
and cell proliferation. In experiment 2, groups of rats were
given two AOM treatments, followed by daily drug gavage
until they were killed ten weeks later, colons were examined
for aberrant crypt foci (ACF) and prostaglandin E 2
production. All drugs significantly enhanced apoptosis and
inhibited ACF, irrespective of their COX-inhibiting potency
(p<0.01), but sulindac was more potent in inhibition of large
ACF, p<0.05. COX-inhibiting sulindac achieved the greatest
protective effect. The greater safety profile of Rac-FB should
provide an advantage for chemoprevention. 
Colorectal Cancer (CRC) is one of the leading causes of
cancer death worldwide (1). A large body of clinical studies
provide strong evidence indicates that the use of non-
steroidal anti-inflammatory drugs (NSAIDs) can reduce the
risk of CRC. Experimental studies have demonstrated that
NSAIDs reduce the incidence of carcinogen-induced colon
tumours in rodents, and several epidemiological
investigations have also shown a 40-50% reduction in the
risk of colorectal adenoma and cancer in individuals taking
NSAIDs (2, 3). Moreover, patients with familial
adenomatous polyposis taking sulindac or other NSAIDs
experience a reduction in adenoma formation (4). The
chemopreventive effects of NSAIDs are at least in part
related to inhibition of cyclooxygenase-2 (COX2), the
inducible isoform of COX that catalyses the conversion of
arachidonic acid to prostaglandin. Approximately 50% of
adenomas and 80% of CRC express high levels of COX2
mRNA and protein in neoplastic tissue (5). However, COX
inhibition in the context of CRC chemoprevention may also
be responsible for NSAIDs toxicity. In fact, the toxicity is
one of the major barriers to wider use of NSAIDs in CRC
prevention. There is growing evidence that a COX-
independent mechanism may be, at least partially,
responsible for the chemopreventive properties of NSAIDs
(6-10). NSAIDs which do not inhibit COX but still are
effective in CRC prevention would represent a significant
advance in prevention or treatment of CRC, with potential
for reduced toxicity. The molecular mechanisms of action of
COX-independent NSAIDs and the timing of their action are
not fully explained (11). Studies are therefore needed to
compare the efficacy of non-COX- inhibiting NSAIDs with
COX-inhibiting ones in order to understand the mechanism
and timing of their action.
Studies in animal models have shown that non-COX-
inhibiting NSAIDs may be useful in primary prevention of
CRC. Sulindac sulfone (a metabolite of the parent Sulindac)
inhibits tumourigenesis in the azoxymethane (AOM)-induced
rat CRC model without suppressing prostaglandin levels
(12). Another potential candidate is the non-COX-inhibiting
R enantiomer of the NSAID flurbiprofen (13). Flurbiprofen
is a member of 2 aryl propionic acid group of NSAIDs and
consists of two enantiomers, of which S flurbiprofen (S-FB)
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is a potent COX inhibitor whereas the R enantiomer (R-FB)
is a much less potent inhibitor of COX. R-FB has been
shown to be protective against intestinal tumourigenesis in
the APCMin/+ mouse (14, 15). But there is about 15-24% bio-
inversion of R-FB to S-FB in mice, and approximately 4%
in rats, whereas in humans R-FB undergoes very little bio-
inversion to S-FB (16), suggesting the rat has a bio-inversion
profile sufficiently similar to humans and which might be
useful for preclinical studies. 
Increased apoptosis and reduced cell proliferation have
been demonstrated for various NSAIDs. Some NSAIDs are
known to be pro-apoptotic in various settings (17). For
example, COX-inhibiting sulindac is known to inhibit
colorectal tumourigenesis by inducing apoptosis of cells
which have already undergone neoplastic transformation in
CRC in vivo (18-20). Non-COX-inhibiting NSAIDs also
induce apoptosis of human colon carcinoma cells (2, 21-23).
However, the effective chemoprevention of colon cancer by
NSAIDs lies in the elimination of DNA-damaged cells that
are inappropriately activated by oncogenic events through the
induction of apoptosis. Hence it is important to examine if
NSAIDs might facilitate apoptotic deletion of DNA-damaged
cells at the time of initiation (before neoplastic
transformation has occurred) in the AOM CRC model, and
if enhanced apoptosis is associated with suppression of early
preneoplastic lesions, formation of aberrant crypt foci (ACF).
The present study was designed to determine the effects of
non-COX-inhibiting R-FB on early apoptotic response to
initiation of oncogenesis and ACF formation in an AOM rat
model, and compare its safety and efficacy with two COX-
inhibiting NSAIDs: sulindac and racemic-flurbiprofen (Rac-
FB, a 50/50 mixture of R and S-FB). 
Materials and Methods
Chemicals. AOM was purchased from Sigma Chemical (St. Louis,
MO, USA); sulindac was supplied by Merck Pty. Ltd (Victoria,
Australia); and Flurbiprofen was a gift from Encore
Pharmaceuticals, CA, USA (Dr. W. Wechter).
Animals. A total of 108 male Sprague-Dawley rats were obtained
from the Animal Resource Centre, Adelaide University, Australia.
The study was approved by the Animal Welfare Committee at
Flinders University (#469/98). Two experiments were performed,
using 48 rats for a short-term experiment and 60 rats for a long-term
experiment. For each experiment, animals were divided randomly
into four equal experimental groups (with comparable initial body
weights), housed in plastic cages (three per cage) and maintained in
a temperature and humidity-controlled animal facility with a 12h
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given free access to water. Animals were weighed weekly and were
monitored daily for clinical signs of ill health throughout the study. 
Diets. The experimental diet (Table I) fed to the animals was based on
a modified American Institute of Nutrition (AIN) -76A diet for rodents
(24). The diet had a protein:carbohydrate:fat balance of 20:55:20 by
weight so as to humanize the fat contribution to energy intake to 35%.
The fat component was 19% olive oil and 1% corn oil. Olive oil was
chosen because it has no effect on eicosanoid production and is not
expect to interact with the NSAIDs. A small amount of corn oil was
used to provide essential fatty acids. Diet was prepared fresh at 4-
weekly intervals, pelleted and stored at –XMFLADMK=
Drugs. The drug groups were: R-FB at 30 mg/kg; Rac-FB at 10
mg/kg and sulindac at 20 mg/kg. R-FB at 30 mg/kg is the maximal
tolerated dose (W Wechter, Loma Linda CA, USA, personal
communication); the 4% bio-inversion of R-FB to S-FB suggests a
dose of 30 mg/kg would be converted to around 1.2 mg/kg of S-FB
in vivo (equivalent to 2.4 mg/kg of Rac-FB). Rac-FB at 10 mg/kg
was chosen because our preliminary study showed that 5 mg/kg of
Rac-FB inhibits prostaglandin E 2 (PGE 2) production, and 10
mg/kg also represents a maximal tolerated dose. The use of two
enantiomers of FB in the studies provides a powerful way to clarify
the importance of the COX inhibitory mechanism. Sulindac at 20
mg /kg was chosen because this is its chemoprotective dose,
showing colon tumour inhibition in a rat CRC model (18). 
Short-term study. Beginning at eight weeks of age, groups of rats
(12/group) were fed a modified AIN diet for two weeks, followed
by one week of drug daily (i.e. R-FB at 30 mg/kg, Rac-FB at 10
mg/kg and sulindac at 20 mg/kg) via gavage. A group without drug
treatment was used as control. At the end of drug treatments, a
single subcutaneous injection of AOM was given at dose of 10
mg/kg to induce DNA damage and acute apoptotic response.
Animals were euthanized by CO2 eight hours later, this being the
time of maximal apoptotic response to AOM in the rat (25). Two
centimeters of distal colon was removed, placed in 10%
paraformaldehyde and embedded in paraffin for study of apoptosis
and cell proliferation (Figure 1A). 
Long-term ACF study. Beginning at five weeks of age, groups of
rats (15/group) were fed a modified AIN diet for two weeks, than
received two consecutive weekly subcutaneous injections of AOM
(15 mg/kg body weight) to induce colonic oncogenesis. After the
second AOM injection, rats were given drug daily (i.e. R-FB at 30
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Table I. Composition of experimental diets. 
Ingredient Modified AIN diet# (g/100g diet) 
Casein 20
Sucrose 20
Olive oil 19
Corn oil 1
Fiber (alpha cell) 5
Corn starch 30
Choline 0.2
Mineral mix‡ 3.5
Vitamin mix 1
Methionine 0.3
#AIN: a modified American Institute of Nutrition (AIN) -76A diet
achieved that had a protein: carbohydrate:fat balance of 20:55:20 by
weight. 
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mg/kg, Rac-FB at 10 mg/kg and sulindac at 20 mg/kg) via gavage.
Rats remained on the same diet throughout the study until killed by
CO2 asphyxiation ten weeks after drug treatment. A group without
drug treatment was used as control. On sacrifice, the entire colon
was rapidly removed, cleaned and fixed flat on Hi-bond C protein
binding paper (GE Healthcare, VWR International, Victoria,
Australia) and fixed in 10% paraformaldehyde. These flat segments
of colon were then stored in 70% ethanol until evaluation for ACF.
Three standard colonic biopsies were also taken from each colon for
PGE2 analysis (Figure 1B). 
Measurement of apoptosis. Paraffin-embedded sections (4 μm) were
stained with haematoxylin and evaluated for the frequency of
colonic epithelial cells undergoing apoptosis as previously described
in detail and validated relative to Terminal Deoxynucleotidyl
Transferase dUTP Nick End Labeling (TUNEL) staining (25).
Twenty colonic crypts were chosen for counting for each rat by an
independent observer unaware of the drug treatment on the basis
that they had a lumen and an intact single row of epithelial cells on
each side. Apoptotic cells were identified by cell shrinkage with a
halo separating them from surrounding cells, nuclear condensation
and formation of apoptotic bodies. Apoptosis was quantified as the
mean number of apoptotic cells per crypt. 
Measurement of cell proliferation. The proliferative activity of colon
epithelial cells was measured using immunohistochemical staining
with monoclonal antibody to Proliferating Cell Nuclear Antigen
(PCNA) (PC-10, Santa Cruz, USA). In brief, the sections were
treated with 0.3% hydrogen peroxide for 20 min to reduce the
endogenous peroxidase activity. Sections were blocked by 10 %
normal horse serum for 30 mins to block non-specific staining. PC-
10 clone PCNA was applied at 1:400 dilution in 10 % normal horse
serum overnight at room temperature. The sections then were
incubated with biotinylated secondary rabbit anti-mouse IgG
(Pharmingen, San Diego, CA, USA) for 30 min and Vectasin ABC
reagent (Vector Laboratories, Burlingame, CA, USA) for 30 min.
Slides were visualized by incubating with 3,3’-diaminobenzamine
(DAB) substrate and counter stained with haematoxylin. The
expression of PCNA was identified by cell nuclei that stained brown
with antibody to PCNA. Proliferation was quantified as the mean
number of PCNA positive cells per crypt. 
Quantification of ACF. The colons were stained with 0.1 %
methylene blue and the number of ACF was counted by examination
at 40×magnification using a dissecting microscope. ACF was
identified by increased size, elevated appearance from the
surrounding mucosa and slit-like shape of the luminal opening and
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Figure 1. Experimental design for short-term (A) and long-term (B) study (ACF) in an (AOM) -induced rat (CRC) model. A: Short-term study:
groups of rats (n=12) were given drug daily by gavage at the age of eight weeks. After one week’s drug treatment, rats were injected with AOM (10
mg/kg) and killed eight hours later. Colons were examined for apoptosis, cell proliferation and crypt height. B: Long-term ACF study: groups of rats
(n=15) were given two weekly AOM treatments (15 mg/kg) followed by drug daily by gavage. Rats were killed ten weeks after AOM treatment and
colons were evaluated for ACF formation and PGE 2 production. 
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scored without knowledge of the dietary treatment. The total
number of ACF per colon was recorded from the distal to proximal
end by a single-blind method, then the average number of ACF of
the colon, with no discrimination of the multiplicity, was determined
as the mean of total ACF/length of section (ACF density/cm). The
number of aberrant crypts with large crypts (>3 crypt/focus) was
also counted. 
PGE 2 analyses. PGE 2 was measured by radioimmunoassay (RIA)
as previously described (26). In brief, three standard colonic biopsies
O=J=L9C=F>JGEL@=<AKL9D=F<G>=9;@;GDGF9F<AF;M:9L=<9LX
in cell culture medium. After 1 hour the medium was collected, and
100 μl sample was mixed with 100 μl RIA buffer and 10 μl of
tritium [3H]-labelled PGE 2 (2 μCi diluted in 10 ml of Na 2CO 3
solution). To this then was added 100 μl of PGE 2 antisera diluted in
.%:M>>=J/9EHD=KO=J=L@=FAF;M:9L=<9LX>GJLOG@GMJK9F<
X>GJGF=@GMJ	 >GDDGO=<:Q;=FLJA>M?AF?	×g) for 20 min.
Scintillant was added and [3H] counted. Concentrations of PGE 2
were estimated by comparison with a standard curve generated from
known standards (26). Each assay was performed in triplicate.
Statistical analysis. Statistical analyses were performed using SPSS
version 17.0 (SPSS Inc., Chicago, IL, USA). Apoptosis, PCNA,
PGE 2 and weight gains were analysed using one-way ANOVA with
correction for multiple comparisons by Tukey’s post-hoc test.
Between-group comparisons of ACF counts were assessed using
logistic and Poisson regression respectively with simple linear
contrasts. Differences between groups were considered significant
when p<0.05. 
Results
General observation. The mean final body weight and
weight gain of the rats under different drug treatments over
the fourteen week period are shown in Table II. The R-FB
drug treatment was well tolerated and led to a weight gain
comparable to that of the control group. In contrast, rats
treated with sulindac (p<0.001) had a significant reduction
in weight gain, compared with the control group. While rats
treated with Rac-FB also had significantly lower body
weight (p<0.01), the weight loss was not as severe as that of
rats treated with sulindac. Nevertheless, all rats survived until
the termination of the ACF experiment; examination of the
small intestine, liver and kidney did not reveal any
abnormality. 
Effects of NSAIDs on apoptosis. All three drugs significantly
enhanced the acute apoptotic response to carcinogen-induced
DNA damage irrespective of their COX-inhibiting potency
compared with the control group p<0.01 (Figure 2A).
Apoptosis was mostly located in the lower compartment of
the crypts, where cells including stem cells form O6-
methylguanine (O6meG) adduct (25), There was no
difference between COX-inhibiting sulindac and Rac-FB,
and non-COX-inhibiting R-FB. 
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Table II. Final body weights and weight gain during 14 weeks of the long-term (ACF) study and colonic (PGE 2) production.
Final body weight Body weight gain PGE 2 production
(g) (g) (ng/100 ml)
Control 705±10a 374±15a 2.5±0.4a
R-FB 30 mg/kg 698±12a 364±11a 2.0±0.4a
Rac-FB 10 mg/kg 654±10b 294±8b 0.5±0.4b
Sulindac 20 mg/kg 531±11c 189±10c 0.45±0.4b
R-FB: R flurbiprofen; S-FB: S flurbiprofen; Rac-FB: a 50/50 mixture of R-FB and S-FB. Values are means±SEM. Values in each column with
different superscripts are statistically different (p<0.05).
Table III. Effects of drugs on the formation of (AOM) -induced (ACF) in rats. 
Total ACF/rat# Large ACF/rat† ACF/cm‡
Control 220±30a 31±4.5a 15±2.0a
R-FB 30 mg/kg 152±10b 38±4.5a 9.3±1.6b
Rac-FB 10 mg/kg 153±16b 13.5±2.6b 10.4±1.5b
Sulindac 20 mg/kg 84±23c 6.7±3.6c 5.5±1.0c
R-FB: R flurbiprofen; S-FB: S flurbiprofen; Rac-FB: a 50/50 mixture of R-FB and S-FB. #Total number of ACF was calculated as the sum of the
small and large ACF. †Large ACF was classified by the number of crypts per focus (≥4). ‡The mean of total ACF/length of section (ACF density/cm).
Values are means±SEM. Values with different superscripts in each column are statistically different (p<0.05).
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Effects of NSAIDs on cell proliferation. None of the drugs
affected the average number of cell per crypt, nor cell
proliferation in the distal colon when expressed as number
of the PCNA-positive cells per crypt (Figure 2B and 2C). 
Effects of NSAIDs on ACF formation. ACF were observed
predominantly in the distal colon. Results are shown in Table
III for total ACF, ACF density and crypt multiplicity (large
ACF). The total number of ACF was significantly reduced
by all three drugs (p<0.01), compared with the control, but
sulindac was more potent than both R-FB and Rac-FB
(p<0.05). Significant reduction was also observed in ACF
density for all three drugs compared with the control group
(p<0.01). However, the numbers of large ACF (with four
crypts per focus or more) were significantly reduced by Rac-
FB (p<0.05) and sulindac (p<0.01), but not by R-FB.
Sulindac was also more effective in reducing large ACF (the
most relevant for predicting subsequent invasive tumour
lesions) than Rac-FB (p<0.05). 
Effects of NSAIDs on mucosal PGE 2. The PGE 2 levels in
the colon are shown in Table Ι. PGE 2 production was
significantly reduced by Rac-FB and sulindac when
compared to the control group (p<0.01), but R-FB did not
significantly affect PGE 2 production. 
Discussion
Some of the protective actions of NSAIDs against CRC
appear to be independent of COX inhibition. It remains to be
clarified whether COX-independent mechanisms are effective
in cancer prevention. R-FB does not inhibit COX and thus
provides the opportunity to directly compare the potency of
different protective mechanisms in CRC prevention. In this
study, we used an AOM rat model to compare the effect of
R-FB with COX-inhibiting NSAIDs sulindac and Rac-FB on
the acute apoptotic response to initiation of oncogenesis and
early preneoplastic lesions, formation of ACF. Our data
suggest all three drugs significantly enhanced the acute
apoptotic response to AOM-induced DNA damage
irrespective of their COX-inhibiting potency. All drugs
significantly reduced the formation of ACF (total ACF and
ACF density), but the number of large ACF was significantly
reduced only by COX-inhibiting NSAIDs sulindac and Rac-
FB, with sulindac showing the greatest protective effect, but
this was accompanied by significant weight loss. Our study
suggests that the enhanced apoptosis during the early stage
of tumor initiation is, in part, responsible for the protection
against ACF by NSAIDs, but COX inhibition appears to be
necessary for better protection when using ACF as a
surrogate biomarker for chemoprevention (27). 
Sulindac has been shown to be effective in suppressing
ACF at a dose of 20 mg/kg/day in the AOM model and it
induces toxicity at this dose (28, 29). Thus, sulindac provides
a useful comparison of toxicity and efficacy with which to
compare R-FB and Rac-FB. Sulindac had potent inhibitory
effect on all measures of ACF compared with R-FB and Rac-
FB. In particular, sulindac significantly inhibited the
formation of large ACF, which is considered to be most
relevant for predicting subsequent invasive tumorous lesions
and is better correlated with the tumour incidence (30).
Martin et al: R-Flurbiprofen and Suppression of Colorectal Oncogenesis
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Figure 2. Effects of drugs on apoptosis, cell proliferation and crypt
height. Apoptotic cells (A), (PCNA)-stained cells (B) and crypt height
(C) of the colonic epithelium of rats for control, 30 mg/kg (R-FB), 10
mg/kg (Rac-FB) and 20 mg/kg sulindac-treated rats eight hours after
(AOM) injection. Statistical significance of drug treatment between the
groups was analysed by ANOVA (*p<0.01, compared with control
group). Data are the mean±SEM.
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However, it also significantly reduced PGE 2 production,
with significant weight loss, thus the toxicity of sulindac
may limit its use for chemoprevention in humans. The reason
for using Rac-FB for comparison is that Rac-FB contains
50% S-FB (COX-inhibiting) and 50% R-FB (non-COX -
inhibiting), thus it provides a reasonable comparison to
determine the importance of COX inhibition. When
comparing the effects of R-FB and Rac-FB on ACF, Rac-FB
appeared to be more effective at reducing large ACF than R-
FB, although it also include a certain degree of toxicity
judged by less weight gain (due to the COX-inhibitory
properties of S-FB). In this regard, Rac-FB appears to have
advantages over sulindac in terms of safety and public health
implications. Given there is no measurable bio-inversion in
humans (31), it is likely the safety of Rac-FB may be further
improved in humans. While R-FB is not as potent as sulindac
and Rac-FB in colon cancer inhibition, R-FB appears to have
a continuous effect throughout the process of colonic
oncogenesis (ACF – adenoma - carcinoma sequence)
because its inhibitory effect on ACF parallels its anti - cancer
effect using colon tumour as endpoint in our previous rat
study (26). A does of 30 mg/kg R-FB is achievable in
human, because this dose in rats would be comparable to the
safe and well tolerated high dose of R-FB (1600 mg/kg) in
humans (32). Sulindac in humans is generally recommended
at a maximum level of 400 mg/day, which would equivalent
to 5 mg/kg in the rat. At this dose, our preliminary data
showed sulindac did not affect ACF formation (unpublished
data), whereas sulindac at 20 mg/kg increased the risk of
COX inhibition-related toxicity (28, 29). In APCMin/+ mice
treated with sulindac, tumour number and size does not
correlate with PGE 2 levels, and so even with COX-
inhibiting NSAIDs, their chemopreventive effect may not be
solely due to COX inhibition (33). However, the relative
potency of these NSAIDs should be cautiously interpreted
from animal studies because the relative toxicity and
therefore the safe dose are species dependent.
Transformation of colorectal epithelia from ACF to
adenoma and adenocarcinoma is associated with a
progressive inhibition of apoptosis and increased cell
proliferation (34). NSAIDs are powerful chemopreventive
agents for CRC, but the stage at which NSAIDs act to
protect has been debated and one group suggests that
multiple stages are affected with differing dependence on
COX inhibition (35). Enhancement of apoptosis is an
important mechanism for the chemopreventive action of
NSAIDs. To date, most evidence for NSAIDs on regulating
apoptosis has been studied in colorectal tumours or
colorectal tumour cells (18-20, 36). In preclinical studies,
NSAIDs are generally administered during the post-initiation
and progression stages and can act relatively late in
tumourigenesis to bring about regression of established
tumours by inducing apoptosis in APCMin/+ mice model and
in rat carcinogen-induced CRC model (12, 20, 37, 38). In
fact, the chemopreventive efficacy of sulindac sulfone
depends on the time of its administration during the
carcinogenic process (2): it increases apoptosis when
administered during the initiation or post-initiation periods,
whereas it has minimal effects on apoptosis when
administered during the promotion/progression stage (2, 39).
However, the possibility that NSAIDs might regulate
apoptotic elimination of DNA-damaged cells at the time of
tumour initiation has not been well characterized. This early
apoptosis in response to genotoxic insult may be a critical
time in tumourigenesis when damaged cells can be
eliminated and therefore tumour initiation prevented. 
One study has shown that NSAIDs suppressed tumour
incidence by enhancing apoptosis of carcinogen-initiated cells
(40). Our data from the present study suggest NSAIDs might
exert their chemopreventive effect, in part, by enhancing acute
apoptosis. A study in our laboratory has shown that the time
course of induction of apoptosis in the colon by AOM (0-72
h) parallels O6-MeG adduct formation (Nyskohus L,
unpublished data). In the gastrointestinal tract, an enhanced
apoptotic response is an important protective process
eliminating cells with DNA damage that may otherwise
progress to malignancy (25, 41). Most importantly, this
apoptotic response is a regulatory target for a variety of
dietary agents and drugs (41-47). Thus NSAIDs may exert a
significant pro-apoptotic effect early in oncogenesis which
protects against persistence of mutations (K-RAS) and
progression to ACF and eventually cancer (48). Up-regulation
of caspase-3 and down-regulation of B-cell lymphoma 2 (Bcl-
2) have been reported to be associated with this early
apoptotic response during tumour initiation (42, 47). These
data together with our previous data suggest that apoptotic
elimination of DNA-damaged cells could explain the reduced
ACF (current study) and tumour formation in rats fed two
categories of NSAIDs (26). Another mechanism for the action
of NSAIDs may be through inhibition of proliferation (28).
While cell proliferation was not affected by all drugs during
short-term study, the inhibition of ACF during long-term
study would suggest the impact of drugs on cell proliferation. 
In conclusion, the effect of NSAIDs on enhancing the
acute apoptotic response to the initiation of carcinogenesis
is irrespective of their COX-inhibiting potency, but a COX-
inhibitory effect is necessary for the best chemopreventive
effect because COX-inhibiting sulindac achieved the greatest
protective effect against ACF formation. The greater safety
profile of Rac-FB should provide an advantage for its use in
chemoprevention. 
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